ID

32230

Beschreibung

Lithium Drug-Drug Interaction Study With Lurasidone HCl; ODM derived from: https://clinicaltrials.gov/show/NCT01074073

Link

https://clinicaltrials.gov/show/NCT01074073

Stichworte

Versionen (1)
  1. 24.10.18 24.10.18 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

24. Oktober 2018

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Schizophrenia NCT01074073

Englisch

Eligibility Schizophrenia NCT01074073

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform.
Beschreibung

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorders

Datentyp

boolean

Alias
UMLS CUI [1]
C0036341
UMLS CUI [2]
C0036337
UMLS CUI [3]
C0036358
2. females who participate in this study:
Beschreibung

Gender

Datentyp

boolean

Alias
UMLS CUI [1]
C0079399
are unable to have children-or-
Beschreibung

Infertility

Datentyp

boolean

Alias
UMLS CUI [1]
C0021359
are willing to remain abstinent from day -5 until 90 days after discharge;
Beschreibung

Sexual Abstinence Willing

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0036899
UMLS CUI [1,2]
C0600109
3. males must be willing to remain sexually abstinent or use an effective method of birth control (e.g. condom) from day -5 until 90 days after discharge.
Beschreibung

Gender Sexual Abstinence Willing | Gender Contraceptive methods | Condoms, Male

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0079399
UMLS CUI [1,2]
C0036899
UMLS CUI [1,3]
C0600109
UMLS CUI [2,1]
C0079399
UMLS CUI [2,2]
C0700589
UMLS CUI [3]
C0009653
4. able and agree to remain off of prior antipsychotic medication for the duration of the study.
Beschreibung

Antipsychotic Agents Absent

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0040615
UMLS CUI [1,2]
C0332197
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. presence or history (within the last year) of a medical or surgical condition (e.g. gastrointestinal disease) that might interfere with the absorption, metabolism, or excretion of orally administered lurasidone.
Beschreibung

Medical condition Interferes with Absorption Lurasidone Oral Product | Medical condition Interferes with Metabolism Lurasidone Oral Product | Medical condition Interferes with Excretion Lurasidone Oral Product | Gastrointestinal Diseases | Operative Surgical Procedure Interferes with Absorption Lurasidone Oral Product | Operative Surgical Procedure Interferes with Metabolism Lurasidone Oral Product | Operative Surgical Procedure Interferes with Excretion Lurasidone Oral Product

Datentyp

boolean

Alias
UMLS CUI [1,1]
C3843040
UMLS CUI [1,2]
C0521102
UMLS CUI [1,3]
C0237442
UMLS CUI [1,4]
C3218141
UMLS CUI [2,1]
C3843040
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C0025519
UMLS CUI [2,4]
C3218141
UMLS CUI [3,1]
C3843040
UMLS CUI [3,2]
C0521102
UMLS CUI [3,3]
C0221102
UMLS CUI [3,4]
C3218141
UMLS CUI [4]
C0017178
UMLS CUI [5,1]
C0543467
UMLS CUI [5,2]
C0521102
UMLS CUI [5,3]
C0237442
UMLS CUI [5,4]
C3218141
UMLS CUI [6,1]
C0543467
UMLS CUI [6,2]
C0521102
UMLS CUI [6,3]
C0025519
UMLS CUI [6,4]
C3218141
UMLS CUI [7,1]
C0543467
UMLS CUI [7,2]
C0521102
UMLS CUI [7,3]
C0221102
UMLS CUI [7,4]
C3218141
2. positive test results within 30 days prior to the start of the study for:
Beschreibung

Positive Laboratory Test Result

Datentyp

boolean

Alias
UMLS CUI [1]
C1335447
3. participated in another clinical trial or receiving an investigational product within 30 days prior to drug administration.
Beschreibung

Study Subject Participation Status | Investigational New Drugs

Datentyp

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
4. use of concomitant medications that prolong the qt/qtc interval within 14 days prior to day - 5 to follow-up
Beschreibung

Pharmaceutical Preparations Causing Prolonged QT interval | Pharmaceutical Preparations Causing Prolonged QTc interval

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0678227
UMLS CUI [1,3]
C0151878
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C0678227
UMLS CUI [2,3]
C1560305
5. use of a monoamine oxidase inhibitor within 21 days prior to day 1 to restabilization.
Beschreibung

Monoamine Oxidase Inhibitors

Datentyp

boolean

Alias
UMLS CUI [1]
C0026457
6. received depot neuroleptics unless the last injection was at least 1 treatment cycle before day -5.
Beschreibung

Injection of depot antipsychotic agent

Datentyp

boolean

Alias
UMLS CUI [1]
C2585377
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Schizophrenia NCT01074073

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorders
Item
1. diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform.
boolean
C0036341 (UMLS CUI [1])
C0036337 (UMLS CUI [2])
C0036358 (UMLS CUI [3])
Gender
Item
2. females who participate in this study:
boolean
C0079399 (UMLS CUI [1])
Infertility
Item
are unable to have children-or-
boolean
C0021359 (UMLS CUI [1])
Sexual Abstinence Willing
Item
are willing to remain abstinent from day -5 until 90 days after discharge;
boolean
C0036899 (UMLS CUI [1,1])
C0600109 (UMLS CUI [1,2])
Gender Sexual Abstinence Willing | Gender Contraceptive methods | Condoms, Male
Item
3. males must be willing to remain sexually abstinent or use an effective method of birth control (e.g. condom) from day -5 until 90 days after discharge.
boolean
C0079399 (UMLS CUI [1,1])
C0036899 (UMLS CUI [1,2])
C0600109 (UMLS CUI [1,3])
C0079399 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
C0009653 (UMLS CUI [3])
Antipsychotic Agents Absent
Item
4. able and agree to remain off of prior antipsychotic medication for the duration of the study.
boolean
C0040615 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Medical condition Interferes with Absorption Lurasidone Oral Product | Medical condition Interferes with Metabolism Lurasidone Oral Product | Medical condition Interferes with Excretion Lurasidone Oral Product | Gastrointestinal Diseases | Operative Surgical Procedure Interferes with Absorption Lurasidone Oral Product | Operative Surgical Procedure Interferes with Metabolism Lurasidone Oral Product | Operative Surgical Procedure Interferes with Excretion Lurasidone Oral Product
Item
1. presence or history (within the last year) of a medical or surgical condition (e.g. gastrointestinal disease) that might interfere with the absorption, metabolism, or excretion of orally administered lurasidone.
boolean
C3843040 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C0237442 (UMLS CUI [1,3])
C3218141 (UMLS CUI [1,4])
C3843040 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C0025519 (UMLS CUI [2,3])
C3218141 (UMLS CUI [2,4])
C3843040 (UMLS CUI [3,1])
C0521102 (UMLS CUI [3,2])
C0221102 (UMLS CUI [3,3])
C3218141 (UMLS CUI [3,4])
C0017178 (UMLS CUI [4])
C0543467 (UMLS CUI [5,1])
C0521102 (UMLS CUI [5,2])
C0237442 (UMLS CUI [5,3])
C3218141 (UMLS CUI [5,4])
C0543467 (UMLS CUI [6,1])
C0521102 (UMLS CUI [6,2])
C0025519 (UMLS CUI [6,3])
C3218141 (UMLS CUI [6,4])
C0543467 (UMLS CUI [7,1])
C0521102 (UMLS CUI [7,2])
C0221102 (UMLS CUI [7,3])
C3218141 (UMLS CUI [7,4])
Positive Laboratory Test Result
Item
2. positive test results within 30 days prior to the start of the study for:
boolean
C1335447 (UMLS CUI [1])
Study Subject Participation Status | Investigational New Drugs
Item
3. participated in another clinical trial or receiving an investigational product within 30 days prior to drug administration.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Pharmaceutical Preparations Causing Prolonged QT interval | Pharmaceutical Preparations Causing Prolonged QTc interval
Item
4. use of concomitant medications that prolong the qt/qtc interval within 14 days prior to day - 5 to follow-up
boolean
C0013227 (UMLS CUI [1,1])
C0678227 (UMLS CUI [1,2])
C0151878 (UMLS CUI [1,3])
C0013227 (UMLS CUI [2,1])
C0678227 (UMLS CUI [2,2])
C1560305 (UMLS CUI [2,3])
Monoamine Oxidase Inhibitors
Item
5. use of a monoamine oxidase inhibitor within 21 days prior to day 1 to restabilization.
boolean
C0026457 (UMLS CUI [1])
Injection of depot antipsychotic agent
Item
6. received depot neuroleptics unless the last injection was at least 1 treatment cycle before day -5.
boolean
C2585377 (UMLS CUI [1])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video